Boston Scientific gets early nod for next-gen S-ICD
This article was originally published in Clinica
The US FDA has approved Boston Scientific's next-generation Emblem S-ICD subcutaneous implantable defibrillator earlier than expected with plans to launch in the US by this fall. The firm has also CE marked the device in Europe.
You may also be interested in...
The global cardiac rhythm management market is set to grow at a compound annual growth rate of 4.8% to about $13.5bn by 2021. This article, based on findings from a Meddevicetracker report, provides an in-depth look at where the growth markets are, the evolving competitive landscape, and discusses the key players and upcoming technological trends that will bolster this market.
Boston Scientific cardiac rhythm management has been struggling to compete with MRI-compatible devices from rival Medtronic.
In 14-6 vote, advisory committee said use of external control comparison to contextualize single-arm trial data demonstrated efficacy and reliance on preclinical data as confirmatory evidence was justified.